Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126914461 | 12691446 | 1 | I | 201405 | 20160816 | 20160826 | 20160826 | EXP | US-PFIZER INC-2016404543 | PFIZER | 82.00 | YR | F | Y | 62.00000 | KG | 20160826 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126914461 | 12691446 | 1 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | PROLONGED-RELEASE CAPSULE | QD | ||||||
| 126914461 | 12691446 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 1 DF, 1X/DAY | 0 | 1 | DF | PROLONGED-RELEASE CAPSULE | QD | ||||||
| 126914461 | 12691446 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 2 DF, 1X/DAY | 0 | 2 | DF | PROLONGED-RELEASE CAPSULE | QD | ||||||
| 126914461 | 12691446 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | PROLONGED-RELEASE CAPSULE | QD | ||||||
| 126914461 | 12691446 | 5 | SS | NEXIUM 24HR | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 22.3 MG, 1X/DAY | 0 | 22.3 | MG | MODIFIED-RELEASE TABLET | QD | ||||||
| 126914461 | 12691446 | 6 | SS | NEXIUM 24HR | ESOMEPRAZOLE MAGNESIUM | 1 | 0 | MODIFIED-RELEASE TABLET | |||||||||||
| 126914461 | 12691446 | 7 | SS | NEXIUM 24HR | ESOMEPRAZOLE MAGNESIUM | 1 | 0 | MODIFIED-RELEASE TABLET | |||||||||||
| 126914461 | 12691446 | 8 | PS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 25 MG, UNK | 74133 | 25 | MG | ||||||||
| 126914461 | 12691446 | 9 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | 74133 | ||||||||||||
| 126914461 | 12691446 | 10 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | 74133 | ||||||||||||
| 126914461 | 12691446 | 11 | SS | ESOMEPRAZOLE MAGNESIUM. | ESOMEPRAZOLE MAGNESIUM | 1 | UNKNOWN | U | 0 | ||||||||||
| 126914461 | 12691446 | 12 | C | VALSARTAN. | VALSARTAN | 1 | Oral | 80 MG, 1X/DAY | 0 | 80 | MG | QD | |||||||
| 126914461 | 12691446 | 13 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 5 MG, 1X/DAY | 0 | 5 | MG | QD | |||||||
| 126914461 | 12691446 | 14 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | QD | |||||||
| 126914461 | 12691446 | 15 | C | LOW DOSE ASPIRIN | ASPIRIN | 1 | Oral | 81.0MG UNKNOWN | 0 | 81 | MG | ||||||||
| 126914461 | 12691446 | 16 | C | LEVOCETIRIZINE | LEVOCETIRIZINE | 1 | UNKNOWN | 0 | |||||||||||
| 126914461 | 12691446 | 17 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | Oral | 1 MG, 1X/DAY | 0 | 1 | MG | QD | |||||||
| 126914461 | 12691446 | 18 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 0.5MG UNKNOWN | 0 | .5 | MG | ||||||||
| 126914461 | 12691446 | 19 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | ||||||||||||
| 126914461 | 12691446 | 20 | C | LVOCETIRIZINE | 2 | Oral | 5 MG, 1X/DAY | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126914461 | 12691446 | 1 | Gastrooesophageal reflux disease |
| 126914461 | 12691446 | 2 | Gastrooesophageal reflux disease |
| 126914461 | 12691446 | 3 | Nausea |
| 126914461 | 12691446 | 5 | Gastrooesophageal reflux disease |
| 126914461 | 12691446 | 6 | Nausea |
| 126914461 | 12691446 | 7 | Gastrooesophageal reflux disease |
| 126914461 | 12691446 | 8 | Ill-defined disorder |
| 126914461 | 12691446 | 9 | Cardiac disorder |
| 126914461 | 12691446 | 10 | Blood pressure abnormal |
| 126914461 | 12691446 | 12 | Blood pressure abnormal |
| 126914461 | 12691446 | 13 | Blood pressure abnormal |
| 126914461 | 12691446 | 14 | Blood cholesterol abnormal |
| 126914461 | 12691446 | 15 | Myocardial infarction |
| 126914461 | 12691446 | 17 | Insomnia |
| 126914461 | 12691446 | 18 | Pain |
| 126914461 | 12691446 | 19 | Anxiety |
| 126914461 | 12691446 | 20 | Hypersensitivity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126914461 | 12691446 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126914461 | 12691446 | Arthropathy | |
| 126914461 | 12691446 | Body height decreased | |
| 126914461 | 12691446 | Cardiac disorder | |
| 126914461 | 12691446 | Contusion | |
| 126914461 | 12691446 | Drug dose omission | |
| 126914461 | 12691446 | Dysgeusia | |
| 126914461 | 12691446 | Dysphagia | |
| 126914461 | 12691446 | Gastric disorder | |
| 126914461 | 12691446 | Gastrointestinal tract irritation | |
| 126914461 | 12691446 | Gastrooesophageal reflux disease | |
| 126914461 | 12691446 | Intentional product use issue | |
| 126914461 | 12691446 | Malaise | |
| 126914461 | 12691446 | Nausea | |
| 126914461 | 12691446 | Oesophageal disorder | |
| 126914461 | 12691446 | Off label use | |
| 126914461 | 12691446 | Oxygen consumption decreased | |
| 126914461 | 12691446 | Pelvic fracture | |
| 126914461 | 12691446 | Product taste abnormal | |
| 126914461 | 12691446 | Skin atrophy | |
| 126914461 | 12691446 | Somnolence | |
| 126914461 | 12691446 | Spinal column stenosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126914461 | 12691446 | 1 | 200405 | 0 | ||
| 126914461 | 12691446 | 4 | 20160815 | 0 | ||
| 126914461 | 12691446 | 5 | 201405 | 20160815 | 0 | |
| 126914461 | 12691446 | 14 | 2000 | 0 | ||
| 126914461 | 12691446 | 15 | 2000 | 0 | ||
| 126914461 | 12691446 | 20 | 2012 | 0 |